Lexeo Therapeutics Inc (LXEO) concluded trading on Wednesday at a closing price of $4.24, with 0.43 million shares of worth about $1.82 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -38.37% during that period and on June 18, 2025 the price saw a gain of about 8.16%. Currently the company’s common shares owned by public are about 33.19M shares, out of which, 25.03M shares are available for trading.
Stock saw a price change of -5.99% in past 5 days and over the past one month there was a price change of 28.88%. Year-to-date (YTD), LXEO shares are showing a performance of -35.56% which decreased to -75.60% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.45 but also hit the highest price of $19.50 during that period. The average intraday trading volume for Lexeo Therapeutics Inc shares is 1.02 million. The stock is currently trading 22.21% above its 20-day simple moving average (SMA20), while that difference is up 30.51% for SMA50 and it goes to -26.69% lower than SMA200.
Lexeo Therapeutics Inc (NASDAQ: LXEO) currently have 33.19M outstanding shares and institutions hold larger chunk of about 90.35% of that.
The stock has a current market capitalization of $140.76M and its 3Y-monthly beta is at 0.45. It has posted earnings per share of -$3.31 in the same period. It has Quick Ratio of 3.42 while making debt-to-equity ratio of 0.11. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for LXEO, volatility over the week remained 4.92% while standing at 7.64% over the month.
Stock’s fiscal year EPS is expected to rise by 14.56% while it is estimated to increase by 23.50% in next year. EPS is likely to grow at an annualized rate of 18.09% for next 5-years, compared to annual growth of -99.98% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Robert W. Baird on June 13, 2024 offering an Outperform rating for the stock and assigned a target price of $28 to it. Coverage by H.C. Wainwright stated Lexeo Therapeutics Inc (LXEO) stock as a Buy in their note to investors on June 06, 2024, suggesting a price target of $22 for the stock. On November 28, 2023, Stifel Initiated their recommendations, while on November 28, 2023, RBC Capital Mkts Initiated their ratings for the stock with a price target of $22. Stock get an Outperform rating from Leerink Partners on November 28, 2023.
